#France #Pierre Fabre #Castres #PFL-721 #PFL-241

Pierre Fabre Laboratories Enhances R&D Portfolio

Pierre Fabre Laboratories has made a significant advancement in its research and development (R&D) efforts by acquiring the global rights to PFL-721 and PFL-241. These compounds, earlier known as STX-721 and STX-241, are promising inhibitors targeting mutant forms of the epidermal growth factor receptor (EGFR) and are particularly focused on addressing unmet medical needs in non-small cell lung cancer (NSCLC).

The acquisition was executed through a deal with Antares Therapeutics, Inc., a subsidiary of Scorpion Therapeutics. With this agreement, Pierre Fabre Laboratories expands its prior collaboration with Scorpion, now gaining complete global rights to these assets and taking a leadership role in their clinical development.

Breakthrough Treatments

PFL-721 is designed as a specific inhibitor for mutations in exon 20 of EGFR, as well as exon 20 of HER2. The clinical trial for PFL-721 will soon optimize its dosing regimen, aiming to develop effective treatment options for patients suffering from NSCLC. On the other hand, PFL-241 is a fourth-generation EGFR mutant-specific inhibitor, with capabilities to penetrate the brain. Current studies are focused on increasing its dosage in clinical trials to combat resistance mutations, specifically C797S, found in NSCLC patients.

Non-small cell lung cancer is the most common subtype of lung cancer. Research indicates that various EGFR mutations drive about 14% to 38% of NSCLC cases, with prevalence rates varying across different geographical locations. This highlights the urgent need for innovative therapies that can effectively target these mutations.

Expanding R&D Capabilities

With this new agreement in place with Antares, Pierre Fabre now holds global rights to a suite of R&D assets, including exarafenib and PFL-002 (previously VERT-002), in addition to PFL-721 and PFL-241. Francesco Hofmann, the director of Research and Development for Pierre Fabre, emphasized the company's commitment to advancing the clinical development of these programs, aiming to deliver novel, differentiated precision medicines to patient populations grappling with significant unmet needs.

Pierre Fabre Laboratories is recognized as the second-largest dermocosmetic company globally and is also a leading pharmaceutical laboratory in Europe. Its dermatology and personal care portfolio includes well-known international brands such as Eau Thermale Avène, Ducray, Klorane, A-Derma, and many others. The company’s healthcare division is dedicated to five primary therapeutic areas: oncology, dermatology, rare diseases, primary care, and family health.

Conclusion

This strategic acquisition marks a pivotal moment for Pierre Fabre Laboratories, reinforcing its commitment to innovation and cancer therapy advancements. With a focused approach on pivotal pharmaceutical research and a robust product pipeline, Pierre Fabre is well-positioned to cater to the growing medical needs of patients worldwide grappling with NSCLC and other treatment-resistant conditions.

This acquisition is a beacon of hope for patients and a significant step forward for Pierre Fabre Laboratories in their quest to enhance the quality of life for those affected by serious health challenges.

For additional insights and updates, please refer to the original press release from Pierre Fabre Laboratories.